Agents and Methods to Elicit Anti-Tumor Immune Response
Agents and Methods to Elicit Anti-Tumor Immune Response
The proposed technology offers to increase activation of CD8+ T-cells to make them more immunogenic against tumors. The inventors have discovered a specific ubiquitin-ligase that hinders proliferation of CD8+ T-cells.
New York, NY, United States
Overview Comments Tagged publications

Background

Cancer Immunotherapies Require Reliable Anti-Tumor Immune Response from CD8+ T-Cells CD8+ T-cells become activated in the immune system in response to tumor cells. Once activated, CD8+ T-cells are recognized as cytotoxic, or killer T-cells, which are capable of inducing the death of infected somatic or tumor cells. However, due to the complex nature of tumor cell recognition, CD8+ cells are not always properly activated and thus, do not elicit an appropriate immunogenic response. Current cancer immunotherapies involve the use of exogenous antibodies, however, the inventors have developed a more directed cell based methodology to increase the probability that CD8+ T-cells will be properly activated to proliferate and elicit an anti-tumor immune response. 

Increased CD8+ T-Cells Activation for Controlled Immunogenic Treatment Against Tumors The proposed technology offers to increase activation of CD8+ T-cells to make them more immunogenic against tumors. The inventors have discovered a specific ubiquitin-ligase that hinders proliferation of CD8+ T-cells. By reducing activity of this ubiquitin-ligase, by means of chemical agents which inhibit expression or activity, knocking out the gene, using interfering RNA (iRNA), or by negating the effects of the endogenous protein, CD8+ T-cells have been shown to proliferate and become more immunogenic against tumors. Using this finding, the inventors developed a method for isolating T-cells with reduced -activity and administering these activated cells to patients in order to induce an anti-tumor immune response in vivo. 

Features: • Immunotherapeutic cancer treatment • Ability to control response of immune system to various tumors by controlling ubiquitinligase expression in CD8+ T-cells 

Advantages: • T-cells will proliferate independently, thus the need to immunize patients with vaccines or cytokines becomes unnecessary • Activation of normally suppressed CD8+ T-cells will enhance the efficiency of the immune system and its ability to respond to tumor cells • Reduction of ubiquitin-ligase levels can be done in cultured cells for later implantation • The described method is non-invasive and can be combined with other treatments 

Publications: • Immunity. 2006 Oct;25(4):571-81. • J Clin Invest. 2007 Apr;117(4):1029-36.

Lead Inventors: Hua Gu, Ph.D.

No comments.
No tagged publications.

Similar innovations

Back
or
Back
Back
or
Back
Back
or
Back
  • Gene therapy for inflammatory and autoimmune diseases
  • This technology comprises inhibitors of antibody production, including IgG, IgA and IgE. These peptide inhibitors are derived from naturally occurring mutations in the CRAF1 (TRAF-3) gene and they specifically inhibit CD40 mediated intracellular signaling. As the CD40-mediated signaling pathway is necessary for B-cell proliferation and antibody production, inhibitors of this pathway act as highly specific and effective immunosuppressants.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
  • Parkinson's and Huntington's Treatment
  • This technology is an antisense oligonucleotide to the protein Nedd2. Nedd2 is an aspartase expressed by neuronal cells and plays a crucial role in apoptosis. When neurons are deprived of cytokines such as nerve growth factor (NGF), Nedd2 expression is upregulated as part of the apoptotic pathway. This technology is an antisense oligonucleotide (ANedd) capable of blocking expression of Nedd2, thereby inhibiting apoptosis.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
← Previous Next → 1 2 3 4 Last
Showing 1-4 from 407

Send Us a Message